Daptomycin. Reassessment of an antibiotic;Daptomicina. Un antibiótico reevaluado

Revista Espanola de Quimioterapia

Volumn 20, Issue 1, 2007, Pages 11-18

  Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CEFTOBIPROLE; CEPHALOSPORIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FLUCLOXACILLIN; GENTAMICIN; LINEZOLID; NAFCILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

BACTEREMIA; EDITORIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FOOD AND DRUG ADMINISTRATION; HUMAN; MORBIDITY; MORTALITY; MYALGIA; MYOSITIS; NONHUMAN; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 34250814536     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (110)

1. Crowcroft, N.S., Catchpole, M. Mortality from methicillin-resistant Staphylococcus aureus in England and Wales: Analysis of death certificates. BMJ 2002; 325: 1390-1391.
2. Levy, S.B. The challenge of antibiotic resistance. Sci Am 1998; 11: 46-53.
3. Cosgrove, S.E., Carmeli, Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
4. Plowman, R. The socioeconomic burden of hospital acquired infection. Euro Surveill 2000; 5: 49-50.
5. Shlaes, D.M., Gerding, D.N., John, F.F. Jr. y cols., Society for Healthcare Epidemiology of American and Infectious Diseases Society of America. Joint Committee on the Prevention of Antimicrobial Resistance. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-599.
6. IDSA (Infectious Diseases Society of America). Bad bugs, no drugs. As antibiotic discovery stagnates, a public health crisis brews. Disponible en http://www.idsociety.org/.
7. IDSA (Infectious Diseases Society of America). Bad bugs, no drugs executive summary. Antibiotic-resistant bacterial pathogens: Why we are concerned? Disponible en http://www.idsociety.org/.
8. NNIS. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31: 481-498.
9. Diekema, D.J., BootsMiller, B.J., Vaughn, T.E. y cols. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004; 38: 78-85.
10. Goosens, H., Ferech, M., Stichele, R.V. y cols., ESAC Group. Outpatients antibiotic use in Europe and association with resistance; a cross-national database study. Lancet 2005; 365: 579-587.
11. Abraham, E.P., Chain, E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 146: 837.
12. Jevons, M.P. 'Celbenin'-resistant staphylococci. BMJ 1961; 1: 124-125.
13. Douthawaite, A.H., Trafford, J.A.P. A new synthetic penicillin. BMJ 1960: 687-690.
14. Barber, M. Methicillin resistant staphylococci. J Clin Pathol 1961; 14: 385-393.
15. Bouza, E., Martínez-Beltrán, J. y Grupo de Trabajo para el Estudio de los Estafilococos. Estudio multicéntrico sobre la prevalencia de estafilococos en España. Enferm Infec Microbiol Clin 1988; 6: 68-79.
16. Oteo, J., Cruchaga, S., Campos, J., Sáez, A., Baquero, F. Antibiotic resistance in blood isolates of Staphylococcus aureus in 31 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2000). Med Clin 2002; 119: 361-365.
17. Cuevas, O., Cercenado, E., Vindel, A. y cols., Spanish Group for the Study of Staphylococcus. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: Five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004; 48: 4240-4245.
18. Hiramatsu, K., Hanaki, H., Ino, T. y cols. Methicillin-resistant Staphylococcus aureus clinical strains with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
19. Centers for Disease Control and Prevention. Sievert, D.M., Boulton M.S., Stolman, G. y cols. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002; 51: 565-567.
20. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR 2000; 48: 1165-1167.
21. Kazakova, S.V., Hageman, J.C., Matava, M. y cols. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352: 468-475.
22. Vandenesch, F., Naimi, T., Enright, M.C. y cols. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003; 9: 978-984.
23. Morin, C.A., Hadler, J.L. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001; 184: 1029-1034.
24. Moellering, R.C. Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2005; 144: 368-370.
25. Creech, C.B., Kernodle, D.S., Alsentzer, A., Wilson, C., Edwards, K.M. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005; 24: 617-621.
26. Miller, L.G., Perdreau-Remington, F., Rieg, G. y cols. Necrotizing fasciitis caused by community associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352: 1445-1453.
27. Hansman, D., Bullen, M.M. A resistant pneumococcus. Lancet 1967; ii: 264-265.
28. Appelbaum, P.C., Koornhof, H.J., Jacobs, M. y cols. Multiple- antibiotic resistance of pneumococci: South Africa. MMWR 1977; 26: 285-286.
29. Appelbaum, P.C., Bhamjee, A., Scragg, J.N. y cols. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1967; ii: 995-997.
30. Jacobs, M.R., Koornhof, H.J., Robins-Browne, R.M. y cols. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299: 725-740.
31. Appelbaum, P.C. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol 1987; 6: 367-377.
32. Muñoz, R., Coffey, T.J., Daniels, M. y cols. Intercontinental spread of a multiresistant clone serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302-306.
33. Casal, J. Antimicrobial susceptibility of Streptococcus pneumoniae: Serotype distribution of penicillin-resistant strains in Spain. Antimicrob Agents Chemother 1982; 22: 222-225.
34. Gobernado, M., Igual, R., Marco, V. y cols. Infecciones neumococicas. Epidemiología, serogrupos y resistencias. Med Clin (Barc.) 1983; 80: 54-59.
35. Liñares, J., Garau, J., Domínguez, G., Pérez, J.L. Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community adquired pneumococal disease. Antimicrob Agents Chemother 1983; 23: 545-547.
36. Fenoll, A., Martín-Bourgon, C., Muñoz, R. y cols. Serotype distribution and antimicrobial resistance in Streptococcus pneumoniae isolates producing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13: 56-60.
37. Liñares, J., Pallarés, R., Alonso, T. y cols. Trends in antimicrobial resistance of clinical isolates of PNE in Bellvitge Hospital, Barcelona, Spain. Clin Infect Dis 1992; 15: 99-105.
38. Novak, R., Henriques, B., Charpentioer, E., Normak, S., Tuomanen, E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999; 399: 590-593.
39. McCullers, J.A., English, B.K., Novak, K. Isolation and characterization of vancomycin-toleram Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000; 181: 369-373.
40. Henriques, B., Norvak, R., Ortqvist, A. y cols. Clinical isolates of Streptococcus pneumoniae that exhibited tolerance of vancomycin. Clin Infect Dis 2001; 32: 552-558.
41. Uttley, A.H., Collins, C.H., Naidoo, J. y cols. Vancomycin resistant enterococci. Lancet 1988; i: 57-58.
42. Leclercq, R., Derlot, E., Duval, J. y cols. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-161.
43. Schouten, M.A., Voss, A., Hoogkamp, J.A., European VRE Study Group. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob Agents Chemother 1999; 43: 2542-2546.
44. st International ASM Conference on Enterococci. Banff, Alberta, Canada, 2000.
45. Kauffman, C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003; 51(Suppl. S3): iit23-iii30.
46. Chow, J.W., Donahedian, S.M., Zervos, M.J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997; 24: 90-91.
47. Mutnick, A.H., Enne, V., Jones, R.N. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother 2003; 37: 769-774.
48. García-Rodríguez, J.A., Muñoz Bellido, J.L. ¿Dispondremos de antimicrobianos adecuados frente a Staphylococcus aureus resistentes a la meticilina? Rev Esp Quimioterap 2006; 19: 313-316.
49. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La. 1980; abst. 68.
50. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La, 1980; abst. 69.
51. Eliopoulos, G.M., Thauvin, C., Gerson, B., Moellering, R.C. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 1985; 25: 357-382.
52. Eliopoulos, G.M., Willey, S., Reiszner, E. y cols. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 1986; 30: 532-535.
53. Tally, F.P., DeBruin, M.F. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000; 46: 523-526.
54. Lakey, J.H., Ptak, M. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry 1988; 27: 4639-4645.
55. Canepari, P., Boaretti, M., Del Mar Lleo, M., Satta, G., Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 1990; 34: 1220-1226.
56. Alborn, W.E., Allen, N.E., Preston, D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 2282-2287.
57. Allen, N.E., Alborn, W.E., Hobbs, J.N. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991; 35: 2639-2642.
58. Boaretti, M., Canepari, P., Lleo, M., Satta, G. The activity of daptomycin on Enterococcus faecium protoplasts: Indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J Antimicrob Chemother 1993; 31: 227-235.
59. Boaretti, M., Canepari, P. Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae. Antimicrob Agents Chemother 1995; 39: 2068-2072.
60. Silverman, J.A., Perlmutter, N.G., Shapiro, H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-2544.
61. Jung, D., Rozek, A., Okon, M., Hancock, R.E. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol 2004; 11: 949-957.
62. Ball L.J., Goult, C.M., Donarski, J.A., Micklefield, J., Ramesh, V. NMR structure determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org Biomol Chem 2004; 2: 1872-1878.
63. Miao, V., Coeffet-LeGal, M.F., Brian, P. y cols. Daptomycin biosynthesis in Streptomyces roseosporus: Cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 2005; 151: 1507-1523.
64. Edmiston, C.E. Jr., Goheen, M.P., Seabrook, G.R. y cols. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006; 192: 344-354.
65. Critchley, I.A., Draghi, D.C., Sahm, D.F. y cols. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003; 51: 639-649.
66. Anastasiou, D.M., Thornem G.M., Luperchiom, S.A., Alderm, J.D. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006; 28: 385-388.
67. Wootton, M., Macgowan, A.P., Walsh, T.R. Comparative bactericidal activity of daptomycin and vancomycin in Staphylococcus aureus with reduced susceptibility to glycopeptides (GISA) and heterogeneous (hGISA). Antimicrob Agents Chemother 2006; 50: 4195-4197.
68. Diederen, B.M., Van Duijn, I., Willemse, P., Kluytmans, J.A. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains. Antimicrob Agents Chemother 2006; 50: 3189-3191.
69. Rand, K.H., Houck, H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-532.
70. Rand, K.H., Houck, H.J. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 2871-2875.
71. Pankey, C., Ashcraft, D., Patel, N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49: 5166-5168.
72. DeRyke, C.A., Sutherland, C., Zhang, B., Nicolau, D.P., Kuti, J.L. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 2006; 50: 3529-3534.
73. Wiedemann, B. Test results: Characterising the antimicrobial activity of daptomycin. Clin Microbiol Infect 2006; 12 (Suppl. 8): 9-14.
74. Green, M R., Anasetti, C., Sandin, R.L., Rolfe, N.E., Greene, J.N. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 2006; 12: 179-181.
75. Kaatz, G.W., Lundstrom, T.S., Seo, S.M. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006; 28: 280-287.
76. Friedman, L., Alder, J.D., Silverman, J.A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2137-2145.
77. Mariani, P.G., Sader, H.S., Jones, R.N. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58: 481-483.
78. Snydman, D.R., Jacobus, N.V., McDermott, L.A., Lonks, J.R., Boyee, J.M. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000; 44: 3447-3450.
79. Rybak, M.J., Hershberger, E., Moldovan, T., Grucz, R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-1066.
80. King, A., Phillips, I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001; 48: 219-223.
81. Barry, A.L., Fuchs, P.C., Brown, S.D. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45: 1919-1922.
82. Fuchs, P.C., Barry, A.L., Brown, S.D. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49: 467-470.
83. Goldstein, E.J., Citron, D.M., Merriam, C.V. y cols. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003; 47: 337-341.
84. Streit, J.M., Jones, R.N., Sader, H.S. Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53: 669-674.
85. Fluit, A.C., Schmitz, F.J., Verhoef, J. y cols. In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004; 48: 1007-1011.
86. Sader, H.S., Streit, J.M., Fritsche, T.R., Jones, R.N. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: Results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006; 12: 844-852.
87. Citron, D.M., Appleman, M.D. In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species. J Clin Microbiol 2006; 44: 3814-3818.
88. Tyrrell, K.L., Citron, D.M., Warren, Y.A. y cols. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 2006; 50: 2728-2731.
89. Wise, R., Andrews, J.M., Ashby, J.P. Activity of daptomycin against Gram-positive pathogens: A comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48: 563-567.
90. Jevitt, L.A., Thorne, G.M., Traczewski, M.M. y cols. Multicenter evaluation of the E-test and disk diffusion methods for differentiating daptomvcin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 2006; 44: 3098-3114.
91. Andrew, J.H., Wale, M.C., Wale, L.J., Greenwood, D. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother 1987; 20: 213-221.
92. Jorgensen, J.H., Crawford, S.A. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs. J Clin Microbiol 2006; 44: 2126-2129.
93. Sader, H.S., Fritsche, T.R., Jones, R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006; 50: 2330-2336.
94. Wise, R., Gee, T., Andrews, J.M. y cols. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002; 46: 31-33.
95. Dvorchik, B., Brazier, D., DeBruin, M., Arbeit, R. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-1323.
96. Benvenuto, M., Benziger, D.P., Yankelev, S., Vigliani, G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-3249.
97. Akins, R.L., Haase, M.R., Levy, E.N. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy 2006; 26: 694-698.
98. English, B.K., Maryniw, E.M., Talati, A.J., Meals, E.A. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob Agents Chemother 2006; 50: 2225-2227.
99. Woodworth, J.R., Nyhart, E.H., Brier, G.L. y cols. Single-doses pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-325.
100. Silverman J.A., Mortin, L.I., Vanpraagh, A.D., Li, T., Alder, J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-2152.
101. Firsov, A.A., Smirnova, M.V., Lubenko, I.Y. y cols. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006; 58: 1185-1192.
102. Arbeit, R.D., Maki, D., Tally, F.P., Campanaro, E., Eisenstein, B.I., Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-1681.
103. Fowler, V.G., Jr., Boucher, H.W., Corey, G.R. y cols., S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 724-727.
104. Kvirikadze, N., Suseno, M., Vescio, T., Kaminer, L., Singh, K. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 2006; 38: 290-292.
105. Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J.M. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 2006; 58: 1208-1214.
106. Antony, S.J. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2006; 38: 293-295.
107. Rao, N., Regalla, D.M. Uncertain efficacy of daptomycin for prosthetic joint infections: A prospective case series. Clin Orthop Relat Res 2006; 451: 34-37.
108. Papadopoulos, S., Ball, A.M., Liewer, S.E. y cols. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42: 108-110.
109. Kazory, K., Dibadj, Weiner, I.D. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006; 57: 578-579.
110. Echevarria, K., Datta, P., Cadena, J., Lewis, J.S. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55: 599-600.